Cargando…

Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients

BACKGROUND: To develop a clinical prediction model and web-based survival rate calculator to predict the overall survival (OS) and cancer-specific survival (CSS) of sarcomatoid renal cell carcinoma (SRCC) for clinical diagnosis and treatment. METHODS: SRCC patient data were retrieved from Surveillan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tong, Wu, Yaohai, Zuo, You, Fu, Shuai, Xu, Zhonghua, Yu, Nengwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947429/
https://www.ncbi.nlm.nih.gov/pubmed/33718077
http://dx.doi.org/10.21037/tau-20-1192
_version_ 1783663225166888960
author Yang, Tong
Wu, Yaohai
Zuo, You
Fu, Shuai
Xu, Zhonghua
Yu, Nengwang
author_facet Yang, Tong
Wu, Yaohai
Zuo, You
Fu, Shuai
Xu, Zhonghua
Yu, Nengwang
author_sort Yang, Tong
collection PubMed
description BACKGROUND: To develop a clinical prediction model and web-based survival rate calculator to predict the overall survival (OS) and cancer-specific survival (CSS) of sarcomatoid renal cell carcinoma (SRCC) for clinical diagnosis and treatment. METHODS: SRCC patient data were retrieved from Surveillance, Epidemiology, and End Results (SEER) database. Factors independently associated with survival were identified by a Cox regression analysis. Nomograms of the prediction model were constructed using a SEER training cohort and validated with a SEER validation cohort. At the same time, the decision analysis curve, receiver operating characteristic curve, and calibration curve were also used to examine and evaluate the model. A web-based survival rate calculator was constructed to help assist in the assessment of the disease condition and clinical prognosis. RESULTS: The records of 2,742 SRCC cases were retrieved from SEER, while 1,921 cases with a median OS of 14 and CSS of 32 months were used as the training cohort. The developed nomograms were more accurate than that of the American Joint Committee on Cancer staging (C-indexes of 0.767 versus 0.725 for OS and 0.775 versus 0.715 for CSS), with better discrimination than that of the American Joint Committee on Cancer (AJCC) stage model and the calibration was validated in the SEER validation cohort. The model’s 3- and 5-year OS and CSS were superior to AJCC and T staging on the analysis decision curve. The prognosis prediction of SRCC established by the prediction model could be evaluated through the web-based survival rate calculator, which plays a guiding role in clinical treatment. CONCLUSIONS: Nomograms and a web-based survival rate calculator predicting the OS and CSS of SRCC patients with better discrimination and calibration were developed.
format Online
Article
Text
id pubmed-7947429
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-79474292021-03-12 Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients Yang, Tong Wu, Yaohai Zuo, You Fu, Shuai Xu, Zhonghua Yu, Nengwang Transl Androl Urol Original Article BACKGROUND: To develop a clinical prediction model and web-based survival rate calculator to predict the overall survival (OS) and cancer-specific survival (CSS) of sarcomatoid renal cell carcinoma (SRCC) for clinical diagnosis and treatment. METHODS: SRCC patient data were retrieved from Surveillance, Epidemiology, and End Results (SEER) database. Factors independently associated with survival were identified by a Cox regression analysis. Nomograms of the prediction model were constructed using a SEER training cohort and validated with a SEER validation cohort. At the same time, the decision analysis curve, receiver operating characteristic curve, and calibration curve were also used to examine and evaluate the model. A web-based survival rate calculator was constructed to help assist in the assessment of the disease condition and clinical prognosis. RESULTS: The records of 2,742 SRCC cases were retrieved from SEER, while 1,921 cases with a median OS of 14 and CSS of 32 months were used as the training cohort. The developed nomograms were more accurate than that of the American Joint Committee on Cancer staging (C-indexes of 0.767 versus 0.725 for OS and 0.775 versus 0.715 for CSS), with better discrimination than that of the American Joint Committee on Cancer (AJCC) stage model and the calibration was validated in the SEER validation cohort. The model’s 3- and 5-year OS and CSS were superior to AJCC and T staging on the analysis decision curve. The prognosis prediction of SRCC established by the prediction model could be evaluated through the web-based survival rate calculator, which plays a guiding role in clinical treatment. CONCLUSIONS: Nomograms and a web-based survival rate calculator predicting the OS and CSS of SRCC patients with better discrimination and calibration were developed. AME Publishing Company 2021-02 /pmc/articles/PMC7947429/ /pubmed/33718077 http://dx.doi.org/10.21037/tau-20-1192 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yang, Tong
Wu, Yaohai
Zuo, You
Fu, Shuai
Xu, Zhonghua
Yu, Nengwang
Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
title Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
title_full Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
title_fullStr Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
title_full_unstemmed Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
title_short Development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
title_sort development and validation of prognostic nomograms and a web-based survival rate calculator for sarcomatoid renal cell carcinoma in pre- and post-treatment patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947429/
https://www.ncbi.nlm.nih.gov/pubmed/33718077
http://dx.doi.org/10.21037/tau-20-1192
work_keys_str_mv AT yangtong developmentandvalidationofprognosticnomogramsandawebbasedsurvivalratecalculatorforsarcomatoidrenalcellcarcinomainpreandposttreatmentpatients
AT wuyaohai developmentandvalidationofprognosticnomogramsandawebbasedsurvivalratecalculatorforsarcomatoidrenalcellcarcinomainpreandposttreatmentpatients
AT zuoyou developmentandvalidationofprognosticnomogramsandawebbasedsurvivalratecalculatorforsarcomatoidrenalcellcarcinomainpreandposttreatmentpatients
AT fushuai developmentandvalidationofprognosticnomogramsandawebbasedsurvivalratecalculatorforsarcomatoidrenalcellcarcinomainpreandposttreatmentpatients
AT xuzhonghua developmentandvalidationofprognosticnomogramsandawebbasedsurvivalratecalculatorforsarcomatoidrenalcellcarcinomainpreandposttreatmentpatients
AT yunengwang developmentandvalidationofprognosticnomogramsandawebbasedsurvivalratecalculatorforsarcomatoidrenalcellcarcinomainpreandposttreatmentpatients